Table 5.
Summary of prognostic factors in multivariate analysis
| Prognostic factors | Hazard ratio (95% CI) | P-value |
|---|---|---|
| Overall survival | ||
| Sex, female vs male | 1.63 (0.63–4.24) | 0.32 |
| Age, <50 years vs ≥50 years | 4.32 (1.64–11.37) | 0.01 |
| T classification, T1–2 vs T3–4 | 0.41 (0.11–1.54) | 0.19 |
| Cervical node metastasis, absent vs present | 18.53 (3.24–105.97) | 0.01 |
| Margin, negative vs positive | 3.48 (1.13–10.78) | 0.03 |
| SAP, present vs absent | 7.93 (2.18–28.82) | 0.01 |
| Histology | 0.01 | |
| Melanoma vs olfactory neuroblastoma | 16.03 (1.54–166.41) | 0.02 |
| Melanoma vs squamous cell carcinoma | 11.97 (1.32–108.71) | 0.03 |
| Melanoma vs others | 4.84 (0.52–44.85) | 0.17 |
| Melanoma vs sarcoma | 1.27 (0.10–16.10) | 0.86 |
| Preoperative therapy, yes vs no | 2.19 (0.63–7.65) | 0.22 |
| Postoperative therapy | 0.19 | |
| Surgery + chemotherapy vs surgery alone | 1.32 (0.44–3.90) | 0.62 |
| Surgery + radiotherapy vs surgery alone | 0.68 (0.18–2.62) | 0.57 |
| Surgery + chemoradiotherapy vs surgery alone | 0.29 (0.08–1.05) | 0.06 |
| Disease-free survival | ||
| Sex, female vs male | 1.27 (0.54–3.00) | 0.59 |
| Age, <50 years vs ≥50 years | 2.59 (1.64–6.02) | 0.03 |
| T classification, T1–2 vs T3–4 | 0.79 (0.23–2.69) | 0.71 |
| Cervical node metastasis, absent vs present | 8.61 (1.70–43.60) | 0.01 |
| Margin, negative vs positive | 2.30 (0.79–6.76) | 0.13 |
| SAP, present vs absent | 7.71 (2.32–25.63) | 0.01 |
| Histology | 0.04 | |
| Melanoma vs olfactory neuroblastoma | 12.86 (1.33–124.21) | 0.03 |
| Melanoma vs squamous cell carcinoma | 12.31 (1.45–104.69) | 0.02 |
| Melanoma vs others | 4.57 (0.53–39.65) | 0.17 |
| Melanoma vs sarcoma | 3.74 (0.34–41.17) | 0.28 |
| Preoperative therapy, yes vs no | 1.49 (0.44–5.00) | 0.52 |
| Postoperative therapy | 0.56 | |
| Surgery + chemotherapy vs surgery alone | 1.09 (0.40–2.99) | 0.87 |
| Surgery + radiotherapy vs surgery alone | 0.78 (0.21–2.91) | 0.71 |
| Surgery + chemoradiotherapy vs surgery alone | 0.46 (0.14–1.50) | 0.20 |
| Recurrence | ||
| Sex, female vs male | 0.87 (0.27–2.77) | 0.87 |
| Age, <50 years vs ≥50 years | 1.79 (0.58–5.52) | 0.31 |
| T classification, T1–2 vs T3–4 | 1.41 (0.26–7.66) | 0.69 |
| Cervical node metastasis, absent vs present | 2.99 (0.24–37.80) | 0.40 |
| Margin, negative vs positive | 0.91 (0.19–4.44) | 0.91 |
| SAP, present vs absent | 7.12 (1.43–35.56) | 0.01 |
| Histology | 0.38 | |
| Melanoma vs olfactory neuroblastoma | 3.54 (0.30–42.17) | 0.32 |
| Melanoma vs squamous cell carcinoma | 7.23 (0.79–66.16) | 0.08 |
| Melanoma vs others | 2.38 (0.24–23.30) | 0.46 |
| Melanoma vs sarcoma | 5.60 (0.44–71.72) | 0.19 |
| Preoperative therapy, yes vs no | 1.07 (0.21–5.47) | 0.94 |
| Postoperative therapy | 0.86 | |
| Surgery + chemotherapy vs surgery alone | 0.76 (0.18–3.24) | 0.71 |
| Surgery + radiotherapy vs surgery alone | 1.14 (0.20–6.55) | 0.88 |
| Surgery + chemoradiotherapy vs surgery alone | 0.60 (0.13–2.66) | 0.50 |
Note: P-values were calculated with a Cox proportional-hazards model.
Abbreviations: CI, confidence interval; vs, versus; SAP, safety anatomic plane.